VOYDEYA Comprehensive Forecast on the Accelerating Market Growth for Paroxysmal Nocturnal Hemoglobinuria, Chronic Urticaria and Dry Macular Degeneration by 2034

[Las Vegas, United States] DelveInsight, a leader in healthcare research firm, has recently published an in-depth report on VOYDEYA, providing insights into the drug market landscape and market forecast of VOYDEYA up to 2034.

Are you interested in finding out the projected market size of VOYDEYA in 2034? VOYDEYA Market Forecast @ https://www.delveinsight.com/sample-request/voydeya-sales-forecast-and-market-size-analysis?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Factors Driving VOYDEYA Growth
1. Strategic Approvals and Regulatory Successes
VOYDEYA has received approvals in major regions:
• Japan: First regulatory approval for adults with PNH, in combination with C5 inhibitors, based on the pivotal ALPHA Phase III trial.
• United States: FDA approved VOYDEYA as an add-on therapy for PNH patients experiencing EVH despite standard therapy.
• European Union: The European Commission approved VOYDEYA as an add-on to ravulizumab or eculizumab for adults with PNH who have residual hemolytic anemia.
• These approvals, supported by orphan drug status, Breakthrough Therapy designation (FDA), and PRIME status (EMA), have significantly lowered development risks and sped regulatory review.

2. Strong ALPHA Phase III Trial Data Supporting Clinical Value
The ALPHA Phase III trial demonstrated clinically meaningful benefits for VOYDEYA as add-on treatment with standard C5 inhibitors:
• Clinically meaningful increases in hemoglobin levels (LSM ~2.9 g/dL) compared with placebo at Week 12.
• Increased rates of transfusion avoidance (~83.3 % of patients with VOYDEYA add-on vs 38.1 % on placebo).
• Long-term extension (up to ~72 weeks) showed sustained improvements in hemoglobin, transfusion avoidance, and fatigue scores.
• These functional benefits address a previously unmet component of PNH care (EVH), validating VOYDEYA'S complementary mechanism to existing therapies and supporting its clinical adoption.

For More Information about VOYDEYA Market Report @ https://www.delveinsight.com/sample-request/voydeya-sales-forecast-and-market-size-analysis?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

The VOYDEYA Market Report offers projected sales forecasts for VOYDEYA for indications until 2034, categorized across the 7MM i.e. United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan. The report also provides extensive coverage and a competitive landscape analysis of competitors and marketed products indication. It also covers analyst views along with market drivers and barriers.

VOYDEYA Drug Summary
VOYDEYA (Danicopan) is an FDA-approved oral complement factor D inhibitor developed by Alexion (AstraZeneca), indicated as an add-on therapy to ravulizumab or eculizumab for treating extravascular hemolysis (EVH) in adults with paroxysmal nocturnal hemoglobinuria (PNH) who experience residual hemolytic anemia despite C5 inhibitor treatment. Administered as 150 mg tablets three times daily (100 mg TID starting dose in severe renal impairment, titratable to 150-200 mg TID), it selectively blocks the alternative complement pathway by preventing factor B cleavage into Ba/Bb fragments, inhibiting C3 convertase formation and downstream opsonization of PNH red blood cells, thereby reducing extravascular macrophage phagocytosis in the spleen/liver. Phase III trials (e.g., VALIANT) demonstrated superiority over placebo, with mean hemoglobin increases of 2.9 g/dL (vs. 0.5 g/dL), reduced fatigue (FACIT-Fatigue +8.0 vs. +1.9), lower absolute reticulocyte counts (-83.8 × 10^9/L vs. -3.5 × 10^9/L), and improved transfusion avoidance; available only via the VOYDEYA REMS program due to infection risks (e.g., meningococcal), with common side effects including headache, nasopharyngitis, diarrhea, pruritus, and elevated liver enzymes. The report provides VOYDEYA's sales, growth barriers and drivers, post usage and approvals in multiple indications.

VOYDEYA Market Recent Developments
In January 2024, VOYDEYA (Danicopan) had been approved in Japan for the treatment of paroxysmal nocturnal haemoglobinuria (PNH). It is indicated in Japan in combination with C5 inhibitor therapy when patients have had an insufficient response to such C5 inhibitors. Voydeya is a first-in-class, oral, Factor D inhibitor developed as add-on to proven standard-of-care Ultomiris or Soliris to address the needs of the subset of patients (approximately 10-20%) with PNH who experience clinically significant extravascular haemolysis (EVH) while treated with a C5 inhibitor. The approval by the Japanese Ministry of Health, Labour and Welfare (MHLW) was based on positive results from the pivotal ALPHA Phase III trial. Results from the 12-week primary evaluation period of the trial were published in The Lancet Haematology.

Do you want to know more information of this report? @ https://www.delveinsight.com/sample-request/voydeya-sales-forecast-and-market-size-analysis?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

What is VOYDEYA Prescribed for?
VOYDEYA is prescribed for the treatment of adults with Paroxysmal Nocturnal Hemoglobinuria, particularly as an add-on therapy to complement C5 inhibitor treatments (such as eculizumab or ravulizumab) in patients who continue to experience extravascular hemolysis; it works by inhibiting complement factor D, thereby helping to reduce the destruction of red blood cells, improve hemoglobin levels, and alleviate symptoms like fatigue and anemia associated with the disease.

VOYDEYA Market Assessment
This report provides a detailed market assessment of VOYDEYA for Paroxysmal Nocturnal Hemoglobinuria, Chronic Urticaria and Dry Macular Degeneration in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2020 to 2034.

VOYDEYA Clinical Assessment
The report provides the clinical trials information of VOYDEYA for Paroxysmal Nocturnal Hemoglobinuria, Chronic Urticaria and Dry Macular Degeneration covering trial interventions, trial conditions, trial status, start and completion dates. Report also includes important insights on regulatory milestones and other developmental activities related.

Do you know your drug's competitive positioning against VOYDEYA? VOYDEYA Drugs Insights @ https://www.delveinsight.com/sample-request/voydeya-sales-forecast-and-market-size-analysis?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

VOYDEYA Competitive Landscape
The report offers insights into the key players and companies actively engaged in the development of the specified indication. It provides valuable information regarding the competitive positioning of the VOYDEYA.

VOYDEYA Market Size in the US
A dedicated section of the report focuses on the expected market size of VOYDEYA for the United States. DelveInsight's analysis includes market trends, growth projections, and key factors influencing the market dynamics, offering a comprehensive perspective for stakeholders.

Why you should buy VOYDEYA Market Report
• The report provides future market assessments for VOYDEYA for Paroxysmal Nocturnal Hemoglobinuria, Chronic Urticaria and Dry Macular Degeneration in the 7 Major Markets, Advance qualitative analysis like SWOT, expert analysts' views, detailed overview of market competitors, and short analysis of other emerging therapies.
• Leading VOYDEYA for Paroxysmal Nocturnal Hemoglobinuria, Chronic Urticaria and Dry Macular Degeneration forecasted market data will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the VOYDEYA
• Discover the competitive landscape of VOYDEYA through 7MM
• Get a Thorough Analysis of the VOYDEYA Development pipeline, Safety & Efficacy of the VOYDEYA, and ROA
• Thorough VOYDEYA market forecast will help understand how drug is competing with other emerging VOYDEYA
• Get analysis of the VOYDEYA clinical trial advancements and the detailed clinical assessment, regulatory and commercial assessment
• Drug Market forecasts are calculated after taking into consideration KOL viewpoints

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.